Last news
Vantage Enhances Its V-Card Premium Payment Experience for CFD Traders

Vantage Enhances Its V-Card Premium Payment Experience for CFD Traders

V-Card combines everyday spending, applicable transaction fees and convenient card management. PORT VILA, Vanuatu, Oct. 23, 2026 /PRNewswire/ -- Vantage Markets ("Vantage") is enhancing its V-Card experience, bringing eligible account-linked payment...

Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

- At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month progression-free survival rate of 81.9% (n=33) in 1L ES-SCLC - Among patients with...

Coreline Soft Receives U.S. FDA 510(k) Clearance for AVIEW Aorta Metrics, Expanding Its Chest CT AI Portfolio in the U.S.

Coreline Soft Receives U.S. FDA 510(k) Clearance for AVIEW Aorta Metrics, Expanding Its Chest CT AI Portfolio in the U.S.

Secures its 13th FDA 510(k) clearance, expanding its U.S. portfolio from lung nodule detection and coronary artery calcium (CAC) analysis to quantitative aortic assessment Enables automated aortic segmentation and diameter measurements across...

2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS

2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS

Registrational Phase 3 G-HOPE-001 Study Met Both Primary Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Overall Survival and Progression-Free Survival Benefits in Previously Treated, CLDN18.2-positive Gastric Cancer...

India's Spiritual Leadership Takes Center Stage Globally: *H.H. Shree Shivkrupanand Swami, promoter of global spritual platform 'Gurutattva' and 'Himalayan Samarpan Meditation', appointed Vice Chair of 'World Meditation Day Governance Committee'

India's Spiritual Leadership Takes Center Stage Globally: *H.H. Shree Shivkrupanand Swami, promoter of global spritual platform 'Gurutattva' and 'Himalayan Samarpan Meditation', appointed Vice Chair of 'World Meditation Day Governance Committee'

NEW DELHI, Oct. 23, 2026 /PRNewswire/ -- In a historic milestone marking India's deepening spiritual footprint and civilizational diplomacy on the world stage, revered Indian spiritual master and founder of Himalayan Samarpan Meditation, His...

Taishin International Bank Opens Flagship Private Banking Branch in Southern Taiwan

Taishin International Bank Opens Flagship Private Banking Branch in Southern Taiwan

Strategic alliance with Switzerland's UBP brings global investment expertise and international wealth management capabilities to Taiwan's growing high-net-worth market TAIPEI, Oct. 23, 2026 /PRNewswire/ -- Taishin International Bank (Taishin Bank)...

Alebund Pharmaceuticals Announces Poster Presentation by Partner R1 Therapeutics of Global Phase IIb Multi-Regional Clinical Trial Design for AP306 at ASN Kidney Week 2026

Alebund Pharmaceuticals Announces Poster Presentation by Partner R1 Therapeutics of Global Phase IIb Multi-Regional Clinical Trial Design for AP306 at ASN Kidney Week 2026

SHANGHAI, Oct. 23, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that its partner, R1 Therapeutics, Inc. ("R1"), presented a...

Financial Report July - September 2026

Financial Report July - September 2026

STOCKHOLM, Oct. 23, 2026 /PRNewswire/ -- Q3 2026: Solid performance in a tough environment Financial highlights Q3 2026 $2,693 million net sales, a decrease of 0.5% 1.1% organic sales decrease* 9.4% operating margin, 9.7% adj. operating margin*...

1 2 3 4 5 6 7 8 9 10 ... 5817
menu
menu